Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 1,702,766 shares at $17.05 ($28.9M) on 2025-10-16, disclosed to the SEC on 2025-10-17.
Scheduled sale ($28.9M) by President & Immunovant CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.93 | 414,683 | $7.0M | 24.3% |
| 2 | $16.93 | 414,683 | $7.0M | 24.3% |
| 3 | $17.05 | 318,282 | $5.4M | 18.8% |
| 4 | $17.05 | 318,282 | $5.4M | 18.8% |
| 5 | $17.06 | 118,418 | $2.0M | 7.0% |
| 6 | $17.06 | 118,418 |
| $2.0M |
| 7.0% |
| Total | $16.99 avg | 1,702,766 | $28.9M | 100% |
| Filing → |
| ROIV | SELL | 2026-09-01 | $7.2M | — | Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |